期刊文献+

rAd-p53联合放化疗治疗晚期头颈部鳞状细胞癌 被引量:1

暂未订购
导出
摘要 p53基因是迄今为止发现与人类肿瘤相关性最高的基因,在头颈部癌中,p53基因在喉癌、上颌窦癌、唾液腺癌、鼻咽癌等中均可见到阳性表达,而以复制缺陷型重组腺病毒为载体的p53基因替代疗法作为一种肿瘤治疗的新方法在头颈部鳞状细胞癌(鳞癌)中取得了很好的疗效,且临床应用安全。自2006年3月至2006年12月,我科应用重组人p53腺病毒(recombinant adenovirus—p53,rAd—p53,商品名为今又生)注射液对14例局部晚期或复发性头颈部鳞癌联合放化疗进行治疗,获得了较好的近期疗效,报道如下。
出处 《中国耳鼻咽喉头颈外科》 北大核心 2009年第2期101-102,共2页 Chinese Archives of Otolaryngology-Head and Neck Surgery
  • 相关文献

参考文献3

二级参考文献32

  • 1孙学华.喉癌治疗失败的原因分析[J].肿瘤防治研究,1994,21(5):317-318. 被引量:1
  • 2甘晓凡,周玉霞,蔡丽萍,刘明霞.中青年喉癌的疗效分析[J].中华耳鼻咽喉科杂志,1996,31(4):201-202. 被引量:1
  • 3Yumi Knegae, Miho Makimura and Izumu Satio. A simple and efficient method for purifica-tion of infections recombinant adenovirus. Jpn J Med Sci Biol, 1994,47:157-166.
  • 4Brand K, Klocke R, Pobetaling A, et al. Induction of apoptosis and G2/M arrest by infection with replication-deficient adenovirus at high multiplicity of infection. Gene Ther, 1999, 6: 1054-1063.
  • 5Li JH, Lax SA,Kim J, et al. The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys,1999, 3:607-616.
  • 6Clayman GL,el-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol, 1998, 6: 2221-2232.
  • 7Gary L, Clayman, Douglas K, et al. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head nad neck cancer. Clin Cancer Res, 1999, 5: 1715-1722.
  • 8Lianglin Zhang, Dihua Yu, Mei Hu, et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res, 2000,60:3655-3661.
  • 9Zhang EP, Lian PG, Cai KL,et al. Radiation therapy of nasopharyngeal carcinoma: prognostic factors based on a 10-year follow-up of 1 302 patients. Int J Radiat Oncol Biol Phys, 1989,16: 301-305.
  • 10Lee AW, Poon YF, Foo W, et al. Retrospective analysis of 5307 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys, 1992,20:261-270.

共引文献127

同被引文献11

  • 1Jemal A,Siegel R,Ward E,et al.Cancer statistics,2008.CA Cancer J Clin,2008,58:71-96.
  • 2Wang SJ,Wong G,de Heer AM,et al.CD44 variantisoforms in head and neck squamous cell carcinomaprogression.Laryngoscope,2009,119:1518-1530.
  • 3Clark JI,Hofmeister C,Choudhury A,et al.Phase IIevaluation of paclitaxel in combination with carboplatin inadvanced head and neck carcinoma.Cancer,2001,92:2334-2340.
  • 4Rowinsky EK,Donehower RC,Jones RJ,et al.Microtubulechanges and cyto-toxicity in leukemic cell lines treated withTaxol.Cancer Res,1988,48:4093-4100.
  • 5Liang Y,Meleady P,Cleary I,et al.Selection withmelphalan or paclitaxel(Taxol)yields variants with differentpatterns of multidrug resistance,integrin expression and invitro invasiveness.Eur J Cancer,2001,37:1041-1052.
  • 6Lu KH,Lue KH,Chou MC,et al.Paclitaxel inducesapoptosis via caspase-3 activation in human osteogenicsarcoma cells(U-2 OS).J Orthop Res,2005,23:988-994.
  • 7Lagas JS,Vlaming ML,van Tellingen O,et al.Multidrugresistance protein 2 is an important determinant of paclitaxelpharmacokinetics.Clin Cancer Res,2006,12:6125-6132.
  • 8Sun N,Sun X,Chen B,et al.MRP2 and GSTP1polymorphisms and chemotherapy response in advanced non-small cell lung cancer.Cancer Chemother Pharmacol,2010,65:437-446.
  • 9Swierniak A,Kimmel M,Smieja J.Mathematical modelingas a tool for planning anticancer therapy.Eur J Pharmacol,2009,625:108-121.
  • 10于亮,李会政,逯素梅,刘闻闻,田家军,李建峰,王海波,徐伟.TWIST在紫杉醇诱导喉癌Hep-2细胞系凋亡中的作用研究[J].中华耳鼻咽喉头颈外科杂志,2009,44(9):772-776. 被引量:2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部